CA2366090C - Composition and method for inducing apoptosis in prostate cancer cells - Google Patents
Composition and method for inducing apoptosis in prostate cancer cells Download PDFInfo
- Publication number
- CA2366090C CA2366090C CA2366090A CA2366090A CA2366090C CA 2366090 C CA2366090 C CA 2366090C CA 2366090 A CA2366090 A CA 2366090A CA 2366090 A CA2366090 A CA 2366090A CA 2366090 C CA2366090 C CA 2366090C
- Authority
- CA
- Canada
- Prior art keywords
- prostate cancer
- dna
- mcc
- cancer cells
- phlei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 105
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title abstract description 33
- 230000006907 apoptotic process Effects 0.000 title description 18
- 230000001939 inductive effect Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 113
- 241000187481 Mycobacterium phlei Species 0.000 claims abstract description 33
- 241001465754 Metazoa Species 0.000 claims abstract description 21
- 210000002421 cell wall Anatomy 0.000 claims abstract description 9
- 210000002307 prostate Anatomy 0.000 claims abstract description 9
- 239000003098 androgen Substances 0.000 claims description 32
- 230000035755 proliferation Effects 0.000 claims description 28
- 229940088597 hormone Drugs 0.000 claims description 18
- 239000005556 hormone Substances 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 230000006882 induction of apoptosis Effects 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 239000000051 antiandrogen Substances 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000000677 immunologic agent Substances 0.000 claims description 4
- 229940124541 immunological agent Drugs 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 3
- 229960003604 testosterone Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 43
- 238000011282 treatment Methods 0.000 abstract description 28
- 201000011510 cancer Diseases 0.000 abstract description 20
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 13
- 229940055036 mycobacterium phlei Drugs 0.000 abstract description 3
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 106
- 241000699670 Mus sp. Species 0.000 description 48
- 108020004414 DNA Proteins 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 14
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 14
- 101710151472 Neuroendocrine convertase 1 Proteins 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000000527 sonication Methods 0.000 description 10
- 238000013467 fragmentation Methods 0.000 description 8
- 238000006062 fragmentation reaction Methods 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000012642 immune effector Substances 0.000 description 7
- 229940121354 immunomodulator Drugs 0.000 description 7
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 6
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000000299 nuclear matrix Anatomy 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 238000010317 ablation therapy Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 5
- 229960001842 estramustine Drugs 0.000 description 5
- 229960005420 etoposide Drugs 0.000 description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 5
- 229960002074 flutamide Drugs 0.000 description 5
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000002601 intratumoral effect Effects 0.000 description 5
- 230000004660 morphological change Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000000064 prostate epithelial cell Anatomy 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000002280 anti-androgenic effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000009702 cancer cell proliferation Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 3
- 239000008365 aqueous carrier Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- -1 but not limited to Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241000187480 Mycobacterium smegmatis Species 0.000 description 2
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 2
- 101710104794 Nuclear mitotic apparatus protein 1 Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 231100000324 minimal toxicity Toxicity 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000011474 orchiectomy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011472 radical prostatectomy Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 2
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 1
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001589086 Bellapiscis medius Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 241000187563 Rhodococcus ruber Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method for treating prostate cancer in an animal, wherein a composition comprising Mycobacterium phlei (M. phlei) DNA (M-DNA) and M-DNA preserved and complexed on M. phlei cell wall (MCC) is administered to the animal in need of such treatment in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of the animal.
Description
Title: COMPOSITION AND METHOD FOR INDUCING APOPTOSIS IN PROSTATE
CANCER CELLS
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application Serial No.
60/127,451 filed April 1, 1999.
FIELD OF INVENTION
The present invention relates to a method for treating prostate cancer.
BACKGROUND OF THE INVENTION
Cancer is an aberrant net accumulation of atypical cells, which can result from an excess of proliferation, an insufficiency of apoptosis, or a combination of the two.
Apoptosis is an active cellular death process characterized by distinctive morphological changes that include condensation of nuclear chromatin, cell shrinkage, nuclear disintegration, plasma membrane blebbing, and the formation of membrane-bound apoptotic bodies (Wyllie et al. Int. Rev. Cytol. 68:251, 1980). A molecular hallmark of apoptosis is degradation of the cell's nuclear DNA into oligonucleosomal-length fragments as the result of activation of endogenous endonucleases (Wyllie A.H.
Nature 284:555, 1981).
Prostate cancer is a major cause of cancer deaths among the male population.
For patients with capsule confined prostate cancer, radical prostatectomy, radiotherapy, a combination of the two, and brachytherapy with radiolabeled seed implants are the most common treatments. Radical prostatectomy can result in impotence and incontinence.
Radiotherapy is associated with prostate specific antigen (PSA) recurrence.
Brachytherapy can be used only in carefully selected patients.
For patients with extracapsular tumors and metastases, androgen ablation and chemotherapy are the most common treatments. Androgen ablation, for use in patients with androgen-dependent prostate cancer, includes surgical castration (bilateral orchiectomy) and chemical castration using anti-androgens and leutinizing hormone production suppressors. Many patients refuse orchiectomy. Anti-androgens and leutinizing hormone production suppressors, used together to effect total androgen blockade, result in androgen withdrawal symptoms and, also, are very expensive.
Moreover, the response to androgen ablation therapy is finite and lasts a medium of 12 to 16 months (Crawford et al. New Eng. J. Med. 321:419, 1989). Enhanced programmed cell death or apoptosis has been identified as a desirable therapeutic outcome in the treatment of prostate cancer (Kyprianou et al., Cancer Surv. 11:265, 1991).
Mutations in p53, a protein that is implicated in the control and induction of apoptosis, are associated with poor clinical prognosis and decreased efficacy of a wide range of therapeutic agents used in the treatment of cancer (Chang et al., J. Clin. Oncol. 13:1009, 1995).
p53 gene mutation, which results in the accumulation of non-functional p53 protein, is known to be associated with a lack of responsiveness to androgen ablation therapy in the treatment of prostate cancer (Navone et al., J. Natl. Cancer Inst. 85:1657, 1993).
Therapeutic agents that are effective in inhibiting the proliferation of and inducing apoptosis in cancer cells in vitro are recognized as having therapeutic utility for the in vivo treatment of cancer (Furukawa et al., J. Surg. Oncol. 48:188, 1991). For example, the anti-proliferative activity in vitro of chemotherapeutic agents towards prostate adenocarcinoma cancer cells has been shown to positively correlate with their in vivo anti-cancer activity (Pienta et al., Prostate 26:270, 1995). The activity of many of these therapeutic agents is however influenced by p53 mutation status, and those agents whose mechanism of action appears to be independent of p53 are non-selective and highly toxic. Chemotherapy, for use in patients with androgen-independent (hormone refractory) prostate cancer, has palliation as its primary goal. However, the toxic side effects of chemotherapy are debilitating, often dose limiting, and compromise the quality of the patient's life.
Castration or androgen ablation therapy (either alone or in combination) induces apoptosis in prostate tumors. The amount of apoptosis occurring in prostate tumors after androgen ablation has been correlated with p53 status (Westin et al., Am. J.
Pathol.
146:1368, 1995). However, almost all patients with metastatic prostate cancer will escape first-line androgen ablation therapy. The induction of apoptosis in prostatic adenocarcinoma following androgen ablation is associated with infiltrating immune effector cells such as cytotoxic T cells and activated macrophages (Landstrom and Funa, Int. J. Cancer 71:451, 1997). The activation of the innate and acquired immune systems, in addition to inhibition of prostate cancer cell proliferation, would be beneficial for the treatment of prostate cancer.
Therefore, there is a need for a novel therapeutic agent for treating prostate cancer that is simple and relatively inexpensive to prepare, that remains therapeutically stable over time, that is effective in the presence of mutated p53, that is capable of stimulating the innate and or the acquired immune system and that is effective at dose regimens that are associated with minimal toxicity even upon repeated administration.
SUMMARY OF THE INVENTION
The present invention satisfies the above need by providing a method for treating prostate cancer in an animal, including a human, wherein a composition comprising Mycobacterium phlei (M. phlei) DNA (M-DNA) and M-DNA, wherein the M-DNA is preserved and is complexed with the M. phlei cell wall (MCC), is administered to the animal in need of such treatment in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of the animal.
M-DNA and MCC are simple and relatively inexpensive to prepare, their activities are reproducible among preparations, they remain therapeutically stable over time, and they are effective at dose regimens that are associated with minimal toxicity even upon repeated administration.
To prepare MCC, M. phlei are grown in liquid medium and harvested. The M.
phlei are disrupted, and the solid components of the disrupted M. phlei are collected by centrifugal sedimentation. The solid components are deproteinized, delipidated, and washed. M-DNA is purified from MCC or is purified directly from M. phlei.
DNase-free reagents are used to minimize DNA degradation (preserve DNA) during preparation of MCC and M-DNA.
A composition comprising M-DNA or MCC and a pharmaceutically acceptable carrier is administered to an animal, including a human, having prostate cancer in an amount effective to prevent, treat or eliminate prostate cancer cells in the animal, including the human, having prostate cancer. Optionally, additional therapeutic agents including, but not limited to, anti-androgens, chemotherapeutic agents, immunomodulatory agents and steroids can be administered with the M-DNA and MCC.
The unexpected and surprising ability of M-DNA and of MCC to prevent, treat or eliminate prostate cancer cells addresses a long felt unfulfilled need in the medical arts and provides an important benefit for animals, including humans.
Accordingly, it is an object of the present invention is to provide a composition and method effective to prevent prostate cancer.
Another object of the present invention is to provide a composition and method effective to prevent hormone sensitive prostate cancer.
Another object of the present invention is to provide a composition and method effective to prevent hormone insensitive prostate cancer.
Another object of the present invention is to provide a method effective to treat prostate cancer.
Another object of the present invention is to provide a method effective to treat hormone sensitive prostate cancer.
Another object of the present invention is to provide a method effective to treat hormone insensitive prostate cancer.
Another object of the present invention is to provide a method effective to eliminate prostate cancer.
Another object of the present invention is to provide a method effective to eliminate hormone sensitive prostate cancer.
Another object of the present invention is to provide a method effective to eliminate hormone insensitive prostate cancer.
Another object of the present invention is to provide a method that has an anti-neoplastic effect on prostate cancer cells.
CANCER CELLS
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application Serial No.
60/127,451 filed April 1, 1999.
FIELD OF INVENTION
The present invention relates to a method for treating prostate cancer.
BACKGROUND OF THE INVENTION
Cancer is an aberrant net accumulation of atypical cells, which can result from an excess of proliferation, an insufficiency of apoptosis, or a combination of the two.
Apoptosis is an active cellular death process characterized by distinctive morphological changes that include condensation of nuclear chromatin, cell shrinkage, nuclear disintegration, plasma membrane blebbing, and the formation of membrane-bound apoptotic bodies (Wyllie et al. Int. Rev. Cytol. 68:251, 1980). A molecular hallmark of apoptosis is degradation of the cell's nuclear DNA into oligonucleosomal-length fragments as the result of activation of endogenous endonucleases (Wyllie A.H.
Nature 284:555, 1981).
Prostate cancer is a major cause of cancer deaths among the male population.
For patients with capsule confined prostate cancer, radical prostatectomy, radiotherapy, a combination of the two, and brachytherapy with radiolabeled seed implants are the most common treatments. Radical prostatectomy can result in impotence and incontinence.
Radiotherapy is associated with prostate specific antigen (PSA) recurrence.
Brachytherapy can be used only in carefully selected patients.
For patients with extracapsular tumors and metastases, androgen ablation and chemotherapy are the most common treatments. Androgen ablation, for use in patients with androgen-dependent prostate cancer, includes surgical castration (bilateral orchiectomy) and chemical castration using anti-androgens and leutinizing hormone production suppressors. Many patients refuse orchiectomy. Anti-androgens and leutinizing hormone production suppressors, used together to effect total androgen blockade, result in androgen withdrawal symptoms and, also, are very expensive.
Moreover, the response to androgen ablation therapy is finite and lasts a medium of 12 to 16 months (Crawford et al. New Eng. J. Med. 321:419, 1989). Enhanced programmed cell death or apoptosis has been identified as a desirable therapeutic outcome in the treatment of prostate cancer (Kyprianou et al., Cancer Surv. 11:265, 1991).
Mutations in p53, a protein that is implicated in the control and induction of apoptosis, are associated with poor clinical prognosis and decreased efficacy of a wide range of therapeutic agents used in the treatment of cancer (Chang et al., J. Clin. Oncol. 13:1009, 1995).
p53 gene mutation, which results in the accumulation of non-functional p53 protein, is known to be associated with a lack of responsiveness to androgen ablation therapy in the treatment of prostate cancer (Navone et al., J. Natl. Cancer Inst. 85:1657, 1993).
Therapeutic agents that are effective in inhibiting the proliferation of and inducing apoptosis in cancer cells in vitro are recognized as having therapeutic utility for the in vivo treatment of cancer (Furukawa et al., J. Surg. Oncol. 48:188, 1991). For example, the anti-proliferative activity in vitro of chemotherapeutic agents towards prostate adenocarcinoma cancer cells has been shown to positively correlate with their in vivo anti-cancer activity (Pienta et al., Prostate 26:270, 1995). The activity of many of these therapeutic agents is however influenced by p53 mutation status, and those agents whose mechanism of action appears to be independent of p53 are non-selective and highly toxic. Chemotherapy, for use in patients with androgen-independent (hormone refractory) prostate cancer, has palliation as its primary goal. However, the toxic side effects of chemotherapy are debilitating, often dose limiting, and compromise the quality of the patient's life.
Castration or androgen ablation therapy (either alone or in combination) induces apoptosis in prostate tumors. The amount of apoptosis occurring in prostate tumors after androgen ablation has been correlated with p53 status (Westin et al., Am. J.
Pathol.
146:1368, 1995). However, almost all patients with metastatic prostate cancer will escape first-line androgen ablation therapy. The induction of apoptosis in prostatic adenocarcinoma following androgen ablation is associated with infiltrating immune effector cells such as cytotoxic T cells and activated macrophages (Landstrom and Funa, Int. J. Cancer 71:451, 1997). The activation of the innate and acquired immune systems, in addition to inhibition of prostate cancer cell proliferation, would be beneficial for the treatment of prostate cancer.
Therefore, there is a need for a novel therapeutic agent for treating prostate cancer that is simple and relatively inexpensive to prepare, that remains therapeutically stable over time, that is effective in the presence of mutated p53, that is capable of stimulating the innate and or the acquired immune system and that is effective at dose regimens that are associated with minimal toxicity even upon repeated administration.
SUMMARY OF THE INVENTION
The present invention satisfies the above need by providing a method for treating prostate cancer in an animal, including a human, wherein a composition comprising Mycobacterium phlei (M. phlei) DNA (M-DNA) and M-DNA, wherein the M-DNA is preserved and is complexed with the M. phlei cell wall (MCC), is administered to the animal in need of such treatment in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of the animal.
M-DNA and MCC are simple and relatively inexpensive to prepare, their activities are reproducible among preparations, they remain therapeutically stable over time, and they are effective at dose regimens that are associated with minimal toxicity even upon repeated administration.
To prepare MCC, M. phlei are grown in liquid medium and harvested. The M.
phlei are disrupted, and the solid components of the disrupted M. phlei are collected by centrifugal sedimentation. The solid components are deproteinized, delipidated, and washed. M-DNA is purified from MCC or is purified directly from M. phlei.
DNase-free reagents are used to minimize DNA degradation (preserve DNA) during preparation of MCC and M-DNA.
A composition comprising M-DNA or MCC and a pharmaceutically acceptable carrier is administered to an animal, including a human, having prostate cancer in an amount effective to prevent, treat or eliminate prostate cancer cells in the animal, including the human, having prostate cancer. Optionally, additional therapeutic agents including, but not limited to, anti-androgens, chemotherapeutic agents, immunomodulatory agents and steroids can be administered with the M-DNA and MCC.
The unexpected and surprising ability of M-DNA and of MCC to prevent, treat or eliminate prostate cancer cells addresses a long felt unfulfilled need in the medical arts and provides an important benefit for animals, including humans.
Accordingly, it is an object of the present invention is to provide a composition and method effective to prevent prostate cancer.
Another object of the present invention is to provide a composition and method effective to prevent hormone sensitive prostate cancer.
Another object of the present invention is to provide a composition and method effective to prevent hormone insensitive prostate cancer.
Another object of the present invention is to provide a method effective to treat prostate cancer.
Another object of the present invention is to provide a method effective to treat hormone sensitive prostate cancer.
Another object of the present invention is to provide a method effective to treat hormone insensitive prostate cancer.
Another object of the present invention is to provide a method effective to eliminate prostate cancer.
Another object of the present invention is to provide a method effective to eliminate hormone sensitive prostate cancer.
Another object of the present invention is to provide a method effective to eliminate hormone insensitive prostate cancer.
Another object of the present invention is to provide a method that has an anti-neoplastic effect on prostate cancer cells.
Another object of the present invention is to provide a method that has an anti-neoplastic effect on hormone-sensitive prostate cancer cells.
Another object of the present invention is to provide a method that has an anti-neoplastic effect on hormone-insensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to inhibit proliferation of prostate cancer cells.
Another object of the present invention is to provide a method effective to inhibit proliferation of prostate cancer cells.
Another object of the present invention is to provide a method effective to inhibit proliferation of hormone sensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to inhibit proliferation of hormone insensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to induce apoptosis in prostate cancer cells.
Another object of the present invention is to provide a method effective to induce apoptosis in hormone sensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to induce apoptosis in hormone insensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to potentiate the activity of other therapeutic agents in the treatment of prostate cancer.
Another object of the present invention is to provide a method effective to potentiate the anti-neoplastic effect of anti-androgenic agents in the treatment of prostate cancer.
Another object of the present invention is to provide a method effective to potentiate the anti-neoplastic effect of chemotherapeutic agents in the treatment of prostate cancer.
Another object of the present invention is to provide a method effective to potentiate the anti-neoplastic effect of radiation in the treatment of prostate cancer.
Another object of the present invention is to provide a method that maintains its effectiveness over time.
These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiment and the appended claims.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1. Inhibition of proliferation of human prostate cancer cells by MCC.
FIG. 2. Inhibition of proliferation of LNCaP and PC3 human prostate cancer cells by M-DNA.
FIG. 3. Inhibition of proliferation of PC3 human prostate cancer cells by MCC
and by DNase I treated MCC.
FIG. 4. Morphological changes in PC3 human prostate cancer cells after treatment with MCC.
FIG. 5. Induction of DNA fragmentation in PC3 human prostate cancer cells by MCC.
FIG. 6. Release of NuMA from (A) LNCaP and (B) PC3 human prostate cancer cells by MCC.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a method for treating prostate cancer in an animal, including a human, wherein a composition comprising a mycobacterial DNA (B-DNA) and B-DNA, wherein the B-DNA is preserved and complexed on a mycobacterial cell wall (BCC), is administered to the animal in need of such treatment in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of the animal.
More particularly, the present invention provides a method for treating prostate cancer in an animal, including a human, wherein a composition comprising Mycobacterium phlei (M. phlei) DNA (M-DNA) and M-DNA, wherein the M-DNA is preserved and complexed on the M. phlei cell wall (MCC), is administered to the animal in need of such treatment in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of the animal.
As used herein, the term "preserved" refers to DNA that has not been degraded into individual bases.
As used herein, the phrase "complexed on" refers to the physical association of M-DNA with M. phlei cell wall.
As used herein, the word "response" refers to inhibition of proliferation of cancer cells, induction of apoptosis in cancer cells, and stimulation of bioactive molecule production by immune system cells.
As used herein, the phrase "bioactive molecules" refers to cytokines and reactive oxygen species.
As used herein, the phrase "immune system cells" refers to macrophages, monocytes, leukocytes, T-cells, B-cells, NK cells, dendritic cells, Langerhan cells, interstitial cells and support cells.
Many bacterial species can be used to practice the present invention including, but not limited to, Coryneform species, Corynebacterium species, Rhodococcus species, Eubacterium species, Bordetella species, Escherichia species, Listeria species, Nocardia species and Mycobacterium species. Preferably, a Mycobacterium species is used including, but not limited to, M. smegmatis, M. fortuitum, M. kansaii, M. tuberculosis, M. bovis, M.
vaccae, M. avium and M. phlei. Most preferably, the Mycobacterium species M.
phlei is used.
Another object of the present invention is to provide a method that has an anti-neoplastic effect on hormone-insensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to inhibit proliferation of prostate cancer cells.
Another object of the present invention is to provide a method effective to inhibit proliferation of prostate cancer cells.
Another object of the present invention is to provide a method effective to inhibit proliferation of hormone sensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to inhibit proliferation of hormone insensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to induce apoptosis in prostate cancer cells.
Another object of the present invention is to provide a method effective to induce apoptosis in hormone sensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to induce apoptosis in hormone insensitive prostate cancer cells.
Another object of the present invention is to provide a method effective to potentiate the activity of other therapeutic agents in the treatment of prostate cancer.
Another object of the present invention is to provide a method effective to potentiate the anti-neoplastic effect of anti-androgenic agents in the treatment of prostate cancer.
Another object of the present invention is to provide a method effective to potentiate the anti-neoplastic effect of chemotherapeutic agents in the treatment of prostate cancer.
Another object of the present invention is to provide a method effective to potentiate the anti-neoplastic effect of radiation in the treatment of prostate cancer.
Another object of the present invention is to provide a method that maintains its effectiveness over time.
These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiment and the appended claims.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1. Inhibition of proliferation of human prostate cancer cells by MCC.
FIG. 2. Inhibition of proliferation of LNCaP and PC3 human prostate cancer cells by M-DNA.
FIG. 3. Inhibition of proliferation of PC3 human prostate cancer cells by MCC
and by DNase I treated MCC.
FIG. 4. Morphological changes in PC3 human prostate cancer cells after treatment with MCC.
FIG. 5. Induction of DNA fragmentation in PC3 human prostate cancer cells by MCC.
FIG. 6. Release of NuMA from (A) LNCaP and (B) PC3 human prostate cancer cells by MCC.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a method for treating prostate cancer in an animal, including a human, wherein a composition comprising a mycobacterial DNA (B-DNA) and B-DNA, wherein the B-DNA is preserved and complexed on a mycobacterial cell wall (BCC), is administered to the animal in need of such treatment in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of the animal.
More particularly, the present invention provides a method for treating prostate cancer in an animal, including a human, wherein a composition comprising Mycobacterium phlei (M. phlei) DNA (M-DNA) and M-DNA, wherein the M-DNA is preserved and complexed on the M. phlei cell wall (MCC), is administered to the animal in need of such treatment in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of the animal.
As used herein, the term "preserved" refers to DNA that has not been degraded into individual bases.
As used herein, the phrase "complexed on" refers to the physical association of M-DNA with M. phlei cell wall.
As used herein, the word "response" refers to inhibition of proliferation of cancer cells, induction of apoptosis in cancer cells, and stimulation of bioactive molecule production by immune system cells.
As used herein, the phrase "bioactive molecules" refers to cytokines and reactive oxygen species.
As used herein, the phrase "immune system cells" refers to macrophages, monocytes, leukocytes, T-cells, B-cells, NK cells, dendritic cells, Langerhan cells, interstitial cells and support cells.
Many bacterial species can be used to practice the present invention including, but not limited to, Coryneform species, Corynebacterium species, Rhodococcus species, Eubacterium species, Bordetella species, Escherichia species, Listeria species, Nocardia species and Mycobacterium species. Preferably, a Mycobacterium species is used including, but not limited to, M. smegmatis, M. fortuitum, M. kansaii, M. tuberculosis, M. bovis, M.
vaccae, M. avium and M. phlei. Most preferably, the Mycobacterium species M.
phlei is used.
Methods to increase anti-neoplastic activity include, but are not limited to, chemically supplementing or biotechnologically amplifying the M-DNA and MCC
with stimulatory sequences or confirmations of DNA derived from the same or different bacterial species; supplementing the M-DNA and MCC with naturally occurring or chemically-synthesized nucleic acids; and, complexing the M-DNA and MCC to natural or synthetic carriers.
Optionally, therapeutic agents including, but not limited to, anti-androgenic, chemotherapeutic, steroidal and immunological agents can be included in the M-DNA and MCC composition of the present invention. M-DNA or MCC and an optional therapeutic agent can be administered simultaneously or sequentially on the same or different schedules.
Anti-androgenic agents include, but are not limited to, flutamide, bicalutamide, nilutamide, megestrol acetate, adrenocorticotropic hormone secretion inhibitors, ketoconazole, estrogens, anti-estrogens and LHRH production suppressors.
Chemotherapeutic agents include, but are not limited to, anti-metabolites, DNA
damaging, microtubule destabilizing, microtubule stabilizing, actin depolymerizing, growth inhibiting, topoisomerase inhibiting, HMG-CoA inhibiting, purine inhibiting, pyrimidine inhibiting, metaloproteinase inhibiting, CDK inhibiting, caspase inhibiting, proteaosome inhibiting, angiogenesis inhibiting, differentiation inducing and immunotherapeutic drugs. These agents include, but are not limited to, anthracycline antibiotics such as doxorubicin and mitoxantrone, estramustine, vinblastine, paclitaxel, etoposide, cyclophosphamide, cisplatin, carboplatin and combinations of the above with or without the addition of steroid drugs.
Immunological agents include, but are not limited to, cytokines, chemokines, interferons, interleukins, polyclonal antibodies and monoclonal antibodies.
Compositions comprising M-DNA and MCC and a pharmaceutically acceptable carrier are prepared by uniformly and intimately bringing into association the M-DNA
and the MCC with liquid carriers, with solid carriers or with both. Liquid carriers include, but are not limited to, aqueous carriers, non-aqueous carriers or both. Solid carriers include, but are not limited to, biological carriers, chemical carriers or both.
M-DNA and MCC can be administered in aqueous suspension, oil emulsion, water in oil emulsion, water-in-oil-in-water emulsion, site-specific emulsion, long-residence emulsion, sticky-emulsion, microemulsion, nanoemulsion, liposomes, microparticles, microspheres, nanospheres, nanoparticles, minipumps, and with various natural or synthetic polymers that allow for sustained release.
Further, M-DNA and MCC can be used with any one, all, or any combination of excipients regardless of the carrier used to present the composition to the responding cells.
These include, but are not limited to, anti-oxidants, buffers, bacteriostats, suspending agents, surfactants and tensio active agents.
In an embodiment, MCC is administered as an aqueous suspension, wherein the size range of the MCC is preferably about 0.025 to 1.000 pm, more preferably from about 0.050 to 0.750 }un and most preferably from about 0.100 to 0.500 pm. The MCC
is suspended in a pharmaceutically acceptable carrier such as, but not limited to, DNase-free water, saline or phosphate buffered saline (PBS) and is homogenized and submicronized by standard procedure such as, but not limited to, sonication and microfluidization. For example, lyophilized MCC is suspended in sterile water and sonicated at 20%
output for 5 min (Model W-385 Sonicator, Heat Systems-Ultrasonics Inc) or microfluidized at 15,000-30,000 psi for one or more flow-throughs (Model M-110Y; Microfluidics, Newton, MA).
The mixture is either aseptically processed or terminally sterilized. An optional therapeutic agent or stabilizing agent can be added to the MCC during submicronization or homogenization or before or after sterilization.
In an embodiment, M-DNA is administrated as an aqueous suspension in the size range preferably from about 2 to > 12 000 b.p, more preferably from about 2 to 250 b.p. and most preferably from about 2 to 20 b.p. The M-DNA is suspended in a pharmaceutically acceptable carrier such as DNase-free water and is homogenized and fragmented by standard procedures such as, but not limited to, sonication and microfluidization. The mixture is aseptically processed or terminally sterilized. An optional therapeutic agent or stabilizing agent can be added to the M-DNA during sonication or homogenization or before or after sterilization For administration in a non-aqueous carrier, M-DNA or MCC are emulsified with a mineral oil or with a neutral oil such as, but not limited to, a diglyceride, a triglyceride, a phospholipid, a lipid, an oil and mixtures thereof, wherein the oil contains an appropriate mix of polyunsaturated and saturated fatty acids. Examples include, but are not limited to, soybean oil, canola oil, palm oil, olive oil and myglyol, wherein the number of fatty acid carbons is between 12 and 22 and wherein the fatty acids can be saturated or unsaturated. Optionally, charged lipid or phospholipid can be suspended in the neutral oil. For example, DNase free phosphatidylcholine is added to DNase free triglyceride soybean oil at a ratio of 1 gram of phospholipid to 20 ml of triglyceride and is dissolved by gentle heating at 50 -60 C. Several grams of MCC are added to a dry autoclaved container and the phospholipid-triglyceride solution is added at a concentration of 20 ml per 1 gram of MCC. The suspension is incubated for 60 min. at 20 C
and is then mixed with DNase-free PBS in the ratio of 20 ml MCC suspension per liter of PBS. The mixture is emulsified by sonication at 20% output for 5 min (Model W-Sonicator, Heat Systems-Ultrasonics Inc.). Optionally, the emulsified mixture is homogenized by microfluidization at 15,000-30,000 psi for one or more flow-throughs (Model M-110Y; Microfluidics). The MCC emulsion is transferred to an autoclaved, capped bottle for storage at 4 C. Optionally a therapeutic agent or a stabilizing agent can be added to the M-DNA or the MCC composition during incubation, emulsification or homogenization.
M-DNA and MCC are administered in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of an animal. The dosage of M-DNA and MCC administered will depend on the stage of the prostate cancer being treated, the organs to which it may have metastasized, the particular formulation, and other clinical factors such as the size, weight and condition of the recipient and the route of administration.
Preferably, the amount of M-DNA and MCC administered is from about 0.00001 to 200 mg/kg per dose, more preferably from about 0.0001 to 100 mg/kg per dose, and most preferably from about 0.001 to 50 mg/kg per dose. Preferably, the M-DNA
content of MCC
is between about 0.001 and 90 mg/100 mg dry MCC, more preferably between about 0.01 and 40 mg/100 mg dry MCC and most preferably between about 0.1 and 30 mg/100 mg dry MCC.
Unexpectedly, we found that at least about 3.6% of the dry weight of MCC is extractable M-DNA.
Routes of administration include, but are not limited to, oral, topical, subcutaneous, intra-prostatic, intra-muscular, intra-peritoneal, intra-venous, intra-arterial, intra-dermal, intra-thecal, intra-lesional, intra-tumoral, intra-bladder, intra-vaginal, intra-ocular, intra-rectal, intra-pulmonary, intra-spinal, transdermal, subdermal, placement within cavities of the body, nasal inhalation, pulmonary inhalation, impression into skin and electrocorporation.
Depending on the route of administration, the volume per dose is preferably about 0.001 to 100 ml per dose, more preferably about 0.01 to 50 ml per dose and most preferably about 0.1 to 30 ml per dose. M-DNA and MCC can be administered in a single dose treatment or in multiple dose treatments on a schedule and over a period of time appropriate to the stage of the prostate cancer being treated, the organs to which it has metastasized, the condition of the recipient and the route of administration.
The following examples will serve to further illustrate the present invention without, at the same time, however, constituting any limitation thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.
EXAMPLE I
Preparation of MCC and M-DNA
MCC was prepared from M. phlei as described in WO 1999/007383.
with stimulatory sequences or confirmations of DNA derived from the same or different bacterial species; supplementing the M-DNA and MCC with naturally occurring or chemically-synthesized nucleic acids; and, complexing the M-DNA and MCC to natural or synthetic carriers.
Optionally, therapeutic agents including, but not limited to, anti-androgenic, chemotherapeutic, steroidal and immunological agents can be included in the M-DNA and MCC composition of the present invention. M-DNA or MCC and an optional therapeutic agent can be administered simultaneously or sequentially on the same or different schedules.
Anti-androgenic agents include, but are not limited to, flutamide, bicalutamide, nilutamide, megestrol acetate, adrenocorticotropic hormone secretion inhibitors, ketoconazole, estrogens, anti-estrogens and LHRH production suppressors.
Chemotherapeutic agents include, but are not limited to, anti-metabolites, DNA
damaging, microtubule destabilizing, microtubule stabilizing, actin depolymerizing, growth inhibiting, topoisomerase inhibiting, HMG-CoA inhibiting, purine inhibiting, pyrimidine inhibiting, metaloproteinase inhibiting, CDK inhibiting, caspase inhibiting, proteaosome inhibiting, angiogenesis inhibiting, differentiation inducing and immunotherapeutic drugs. These agents include, but are not limited to, anthracycline antibiotics such as doxorubicin and mitoxantrone, estramustine, vinblastine, paclitaxel, etoposide, cyclophosphamide, cisplatin, carboplatin and combinations of the above with or without the addition of steroid drugs.
Immunological agents include, but are not limited to, cytokines, chemokines, interferons, interleukins, polyclonal antibodies and monoclonal antibodies.
Compositions comprising M-DNA and MCC and a pharmaceutically acceptable carrier are prepared by uniformly and intimately bringing into association the M-DNA
and the MCC with liquid carriers, with solid carriers or with both. Liquid carriers include, but are not limited to, aqueous carriers, non-aqueous carriers or both. Solid carriers include, but are not limited to, biological carriers, chemical carriers or both.
M-DNA and MCC can be administered in aqueous suspension, oil emulsion, water in oil emulsion, water-in-oil-in-water emulsion, site-specific emulsion, long-residence emulsion, sticky-emulsion, microemulsion, nanoemulsion, liposomes, microparticles, microspheres, nanospheres, nanoparticles, minipumps, and with various natural or synthetic polymers that allow for sustained release.
Further, M-DNA and MCC can be used with any one, all, or any combination of excipients regardless of the carrier used to present the composition to the responding cells.
These include, but are not limited to, anti-oxidants, buffers, bacteriostats, suspending agents, surfactants and tensio active agents.
In an embodiment, MCC is administered as an aqueous suspension, wherein the size range of the MCC is preferably about 0.025 to 1.000 pm, more preferably from about 0.050 to 0.750 }un and most preferably from about 0.100 to 0.500 pm. The MCC
is suspended in a pharmaceutically acceptable carrier such as, but not limited to, DNase-free water, saline or phosphate buffered saline (PBS) and is homogenized and submicronized by standard procedure such as, but not limited to, sonication and microfluidization. For example, lyophilized MCC is suspended in sterile water and sonicated at 20%
output for 5 min (Model W-385 Sonicator, Heat Systems-Ultrasonics Inc) or microfluidized at 15,000-30,000 psi for one or more flow-throughs (Model M-110Y; Microfluidics, Newton, MA).
The mixture is either aseptically processed or terminally sterilized. An optional therapeutic agent or stabilizing agent can be added to the MCC during submicronization or homogenization or before or after sterilization.
In an embodiment, M-DNA is administrated as an aqueous suspension in the size range preferably from about 2 to > 12 000 b.p, more preferably from about 2 to 250 b.p. and most preferably from about 2 to 20 b.p. The M-DNA is suspended in a pharmaceutically acceptable carrier such as DNase-free water and is homogenized and fragmented by standard procedures such as, but not limited to, sonication and microfluidization. The mixture is aseptically processed or terminally sterilized. An optional therapeutic agent or stabilizing agent can be added to the M-DNA during sonication or homogenization or before or after sterilization For administration in a non-aqueous carrier, M-DNA or MCC are emulsified with a mineral oil or with a neutral oil such as, but not limited to, a diglyceride, a triglyceride, a phospholipid, a lipid, an oil and mixtures thereof, wherein the oil contains an appropriate mix of polyunsaturated and saturated fatty acids. Examples include, but are not limited to, soybean oil, canola oil, palm oil, olive oil and myglyol, wherein the number of fatty acid carbons is between 12 and 22 and wherein the fatty acids can be saturated or unsaturated. Optionally, charged lipid or phospholipid can be suspended in the neutral oil. For example, DNase free phosphatidylcholine is added to DNase free triglyceride soybean oil at a ratio of 1 gram of phospholipid to 20 ml of triglyceride and is dissolved by gentle heating at 50 -60 C. Several grams of MCC are added to a dry autoclaved container and the phospholipid-triglyceride solution is added at a concentration of 20 ml per 1 gram of MCC. The suspension is incubated for 60 min. at 20 C
and is then mixed with DNase-free PBS in the ratio of 20 ml MCC suspension per liter of PBS. The mixture is emulsified by sonication at 20% output for 5 min (Model W-Sonicator, Heat Systems-Ultrasonics Inc.). Optionally, the emulsified mixture is homogenized by microfluidization at 15,000-30,000 psi for one or more flow-throughs (Model M-110Y; Microfluidics). The MCC emulsion is transferred to an autoclaved, capped bottle for storage at 4 C. Optionally a therapeutic agent or a stabilizing agent can be added to the M-DNA or the MCC composition during incubation, emulsification or homogenization.
M-DNA and MCC are administered in an amount effective to have an anti-neoplastic effect on cancer cells in the prostate of an animal. The dosage of M-DNA and MCC administered will depend on the stage of the prostate cancer being treated, the organs to which it may have metastasized, the particular formulation, and other clinical factors such as the size, weight and condition of the recipient and the route of administration.
Preferably, the amount of M-DNA and MCC administered is from about 0.00001 to 200 mg/kg per dose, more preferably from about 0.0001 to 100 mg/kg per dose, and most preferably from about 0.001 to 50 mg/kg per dose. Preferably, the M-DNA
content of MCC
is between about 0.001 and 90 mg/100 mg dry MCC, more preferably between about 0.01 and 40 mg/100 mg dry MCC and most preferably between about 0.1 and 30 mg/100 mg dry MCC.
Unexpectedly, we found that at least about 3.6% of the dry weight of MCC is extractable M-DNA.
Routes of administration include, but are not limited to, oral, topical, subcutaneous, intra-prostatic, intra-muscular, intra-peritoneal, intra-venous, intra-arterial, intra-dermal, intra-thecal, intra-lesional, intra-tumoral, intra-bladder, intra-vaginal, intra-ocular, intra-rectal, intra-pulmonary, intra-spinal, transdermal, subdermal, placement within cavities of the body, nasal inhalation, pulmonary inhalation, impression into skin and electrocorporation.
Depending on the route of administration, the volume per dose is preferably about 0.001 to 100 ml per dose, more preferably about 0.01 to 50 ml per dose and most preferably about 0.1 to 30 ml per dose. M-DNA and MCC can be administered in a single dose treatment or in multiple dose treatments on a schedule and over a period of time appropriate to the stage of the prostate cancer being treated, the organs to which it has metastasized, the condition of the recipient and the route of administration.
The following examples will serve to further illustrate the present invention without, at the same time, however, constituting any limitation thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.
EXAMPLE I
Preparation of MCC and M-DNA
MCC was prepared from M. phlei as described in WO 1999/007383.
All reagents were selected to preserve the DNA.
M-DNA was prepared from M. phlei and from MCC as described in WO 1999/007383. All reagents were selected to enhance conservation of (preserve) the DNA.
Unless stated otherwise, M-DNA and MCC were suspended in DNase-free water or in a pharmaceutically acceptable DNase-free buffer and sonicated. The particle size of MCC was evaluated during sonication by photon correlation spectroscopy (Zetasizer 3000, Malvern Instruments, Malvern, Worcester, England). The diameter of MCC
decreased gradually with sonication (Table 1). The molecular weight of M-DNA
was evaluated during sonication by electrophoresis in 2.0 % agarose gel containing 0.5 pg/ml ethidium bromide (3 hours at 100 V). The molecular weight of M-DNA decreased gradually with sonication (Table 2).
Table 1 MCC diameter Sonication (minutes) Z average mean (nm) 0 > 10 000 15 Table M-DNA molecular weight Sonication (minutes) Molecular weight (b.p.) 0 > 12 000 0.5 < 100 15 < 20 M-DNA and MCC did not contain endotoxins as determined using a Limulus amebocyte lysate sensitivity QCL-1000TM kit (BioWhittaker, Walkersville, MD).
The Limulus amebocyte lysate sensitivity of this assay is 5.5 pg endotoxin/ml.
M-DNA was prepared from M. phlei and from MCC as described in WO 1999/007383. All reagents were selected to enhance conservation of (preserve) the DNA.
Unless stated otherwise, M-DNA and MCC were suspended in DNase-free water or in a pharmaceutically acceptable DNase-free buffer and sonicated. The particle size of MCC was evaluated during sonication by photon correlation spectroscopy (Zetasizer 3000, Malvern Instruments, Malvern, Worcester, England). The diameter of MCC
decreased gradually with sonication (Table 1). The molecular weight of M-DNA
was evaluated during sonication by electrophoresis in 2.0 % agarose gel containing 0.5 pg/ml ethidium bromide (3 hours at 100 V). The molecular weight of M-DNA decreased gradually with sonication (Table 2).
Table 1 MCC diameter Sonication (minutes) Z average mean (nm) 0 > 10 000 15 Table M-DNA molecular weight Sonication (minutes) Molecular weight (b.p.) 0 > 12 000 0.5 < 100 15 < 20 M-DNA and MCC did not contain endotoxins as determined using a Limulus amebocyte lysate sensitivity QCL-1000TM kit (BioWhittaker, Walkersville, MD).
The Limulus amebocyte lysate sensitivity of this assay is 5.5 pg endotoxin/ml.
Preparation of B-DNA and BCC
B-DNA and BCC are prepared from M. smegmatis, M. fortuitous, Nocardia rubra, Nocardia asteroides, Cornybacterium parvum, M. kansaii, M tuberculosis and M.
bovis as in Example 1.
DNase I treatment Treatment of M-DNA and MCC with DNase I was carried out as described in WO 1999/007383. DNase I digests both single stranded and double stranded DNA and causes almost total degradation of the DNA.
Cells and reagents Human PC3 and DU-145 androgen-independent and LNCaP androgen-dependent prostate cancer cells were obtained from the ATCC (#CRL-1435, HTB-81 and CRL-1740, respectively). Primary human prostate epithelial cells (PrEc) were obtained from Clonetics (#CC-2555, Walkersville, MD, USA). All cell lines were cultured as recommended by the supplier. PC3, DU-145, LNCaP and PrEc cells were seeded at cells/ml of growth medium in 6-well flat bottom microplates and allowed to grow for 24 h at 37 C in 5% CO2. At 24 h, growth medium was replaced with growth medium containing M-DNA or MCC.
Inhibition of prostate cancer cell proliferation by MCC
Cell proliferation was determined using dimethylthiazoldiphenyltetrazolium bromide (MTT) reduction (Mosman et al. J. of Immunol. Meth. 65:55, 1983).
PC3, DU-145 and LNCaP prostate cancer cells and PrEc prostate epithelial cells were incubated with 0, 0.01, 0.10, 1, 10 and 100 pg/ml of MCC. After 48 h, 100 p1 of MTT in 5mg/ml phosphate buffered saline was added to each well and incubation was continued for 4 h. Medium was then aspirated from each well, 1 ml of acidified isopropyl alcohol was added, and reduced MTT was solubilized by mixing. The absorbence of the reaction product was determined at 570 nm. MCC at 1, 10 and 100 i.ig/ml inhibited proliferation of androgen-dependent LNCaP prostate cancer cells and of androgen-independent PC3 and DU-145 prostate cancer cells, but did not inhibit proliferation of PrEc normal prostate cells (Fig. 1).
These data demonstrate that MCC inhibits proliferation of both androgen-independent and androgen-dependent prostate cancer cells in the absence of immune effector cells. MCC does not inhibit proliferation of normal prostate cells.
Inhibition of prostate cancer cell proliferation by M-DNA
B-DNA and BCC are prepared from M. smegmatis, M. fortuitous, Nocardia rubra, Nocardia asteroides, Cornybacterium parvum, M. kansaii, M tuberculosis and M.
bovis as in Example 1.
DNase I treatment Treatment of M-DNA and MCC with DNase I was carried out as described in WO 1999/007383. DNase I digests both single stranded and double stranded DNA and causes almost total degradation of the DNA.
Cells and reagents Human PC3 and DU-145 androgen-independent and LNCaP androgen-dependent prostate cancer cells were obtained from the ATCC (#CRL-1435, HTB-81 and CRL-1740, respectively). Primary human prostate epithelial cells (PrEc) were obtained from Clonetics (#CC-2555, Walkersville, MD, USA). All cell lines were cultured as recommended by the supplier. PC3, DU-145, LNCaP and PrEc cells were seeded at cells/ml of growth medium in 6-well flat bottom microplates and allowed to grow for 24 h at 37 C in 5% CO2. At 24 h, growth medium was replaced with growth medium containing M-DNA or MCC.
Inhibition of prostate cancer cell proliferation by MCC
Cell proliferation was determined using dimethylthiazoldiphenyltetrazolium bromide (MTT) reduction (Mosman et al. J. of Immunol. Meth. 65:55, 1983).
PC3, DU-145 and LNCaP prostate cancer cells and PrEc prostate epithelial cells were incubated with 0, 0.01, 0.10, 1, 10 and 100 pg/ml of MCC. After 48 h, 100 p1 of MTT in 5mg/ml phosphate buffered saline was added to each well and incubation was continued for 4 h. Medium was then aspirated from each well, 1 ml of acidified isopropyl alcohol was added, and reduced MTT was solubilized by mixing. The absorbence of the reaction product was determined at 570 nm. MCC at 1, 10 and 100 i.ig/ml inhibited proliferation of androgen-dependent LNCaP prostate cancer cells and of androgen-independent PC3 and DU-145 prostate cancer cells, but did not inhibit proliferation of PrEc normal prostate cells (Fig. 1).
These data demonstrate that MCC inhibits proliferation of both androgen-independent and androgen-dependent prostate cancer cells in the absence of immune effector cells. MCC does not inhibit proliferation of normal prostate cells.
Inhibition of prostate cancer cell proliferation by M-DNA
PC3 and LNCaP prostate cancer cells were incubated with 10 and 100 pg/ml of M-DNA. Cell proliferation was determined as in Example 5. M-DNA at 10 and 100 pg/ml inhibited proliferation of PC3 prostate cancer cells (Fig. 2). These data demonstrate that M-DNA inhibits proliferation of androgen-dependent and androgen-independent prostate cancer cells in the absence of immune effector cells.
Inhibition of prostate cancer cell proliferation by MCC and by DNase I treated MCC
PC3 prostate cancer cells were incubated with 1 Unit/ml DNase I, with 1 pg/ml MCC and with 1 pg/ml DNase I treated MCC.
DNase I inhibited proliferation PC3 cancer cells about 5%, MCC inhibited proliferation PC3 cancer cells about 50% and DNase I treated MCC inhibited proliferation of PC3 cancer cells about 30% (Fig. 3).
These data demonstrate that MCC inhibits proliferation of androgen-independent prostate cancer cells in the absence of immune effector cells.
Further, these data demonstrate that treatment of MCC with DNase I reduces the anti-proliferative effect of MCC.
Induction of apoptosis as indicated by morphological changes Morphological changes indicative of cell death by apoptosis include condensation of nuclear chromatin, cell shrinkage, nuclear disintegration, plasma membrane blebbing and the formation of membrane-bound bodies (Wyllie et al. Int. Rev. Cytol.
68:251,1980).
PC3 prostate cancer cells were incubated with 0 and with 200 pg/ml of MCC for h. Images were collected on a light microscope with a 40 x 2.5 NA Apochromat objective.
Cells incubated with 0 pg/ml MCC exhibited normal morphology, whereas cells incubated with 200 pg/ml MCC exhibited striking morphological changes indicative of cell death by apoptosis (Fig. 4).
These date demonstrate that MCC induces apoptosis in androgen-independent prostate cancer cells in the absence of immune effector cells.
Induction of apoptosis as indicated by DNA fragmentation Fragmentation of cellular DNA into nucleosome-sized fragments by the activation of endogenous endonucleases is characteristic of cells undergoing apoptosis (Wyllie A.H.
Nature 284:555, 1981; Newell et al. Nature 357:286, 1990).
During routine monolayer culture of PC3 cells, a considerable number of cells detached from the plastic surface of the tissue culture wells and floated in the medium (Palayoor et al., Radiation Res. 148:105, 1997). After 48 hours of treatment with MCC, the proportion of detached cells increased. Therefore, DNA fragmentation was analyzed both in detached and in attached PC3 cells (Smith et al. Nature 337:795, 1989).
Inhibition of prostate cancer cell proliferation by MCC and by DNase I treated MCC
PC3 prostate cancer cells were incubated with 1 Unit/ml DNase I, with 1 pg/ml MCC and with 1 pg/ml DNase I treated MCC.
DNase I inhibited proliferation PC3 cancer cells about 5%, MCC inhibited proliferation PC3 cancer cells about 50% and DNase I treated MCC inhibited proliferation of PC3 cancer cells about 30% (Fig. 3).
These data demonstrate that MCC inhibits proliferation of androgen-independent prostate cancer cells in the absence of immune effector cells.
Further, these data demonstrate that treatment of MCC with DNase I reduces the anti-proliferative effect of MCC.
Induction of apoptosis as indicated by morphological changes Morphological changes indicative of cell death by apoptosis include condensation of nuclear chromatin, cell shrinkage, nuclear disintegration, plasma membrane blebbing and the formation of membrane-bound bodies (Wyllie et al. Int. Rev. Cytol.
68:251,1980).
PC3 prostate cancer cells were incubated with 0 and with 200 pg/ml of MCC for h. Images were collected on a light microscope with a 40 x 2.5 NA Apochromat objective.
Cells incubated with 0 pg/ml MCC exhibited normal morphology, whereas cells incubated with 200 pg/ml MCC exhibited striking morphological changes indicative of cell death by apoptosis (Fig. 4).
These date demonstrate that MCC induces apoptosis in androgen-independent prostate cancer cells in the absence of immune effector cells.
Induction of apoptosis as indicated by DNA fragmentation Fragmentation of cellular DNA into nucleosome-sized fragments by the activation of endogenous endonucleases is characteristic of cells undergoing apoptosis (Wyllie A.H.
Nature 284:555, 1981; Newell et al. Nature 357:286, 1990).
During routine monolayer culture of PC3 cells, a considerable number of cells detached from the plastic surface of the tissue culture wells and floated in the medium (Palayoor et al., Radiation Res. 148:105, 1997). After 48 hours of treatment with MCC, the proportion of detached cells increased. Therefore, DNA fragmentation was analyzed both in detached and in attached PC3 cells (Smith et al. Nature 337:795, 1989).
Detached cells were collected and centrifuged at 350 X G for 5 min. The pellet of detached cells and the remaining attached cells were lysed in 50p1 of buffer containing 50 mM Tris-HC1 (pH 8.0), 10 mM EDTA, 0.5 % (w/v) sodium lauryl sarcosinate (SDS) and 0.5 mg/ml proteinase K (Sigma-Aldrich Canada, Oakville, Ontario) at 55 C for 1 h.
Ten p1 of 0.5 mg/ml RNase A (Sigma-Aldrich Canada) was added to each sample and the incubation was continued for 1 h. Samples were heated to 65 C and 10 p1 of 10 mM EDTA
(pH 8.0) containing 1 % (w/v) low-gelling-temperature agarose, 0.25 % (w/v) bromophenol blue, 40 % (w/v) sucrose was mixed with each sample. The samples were electrophoresed at 100 V for 3 h in a 2 % agarose gel containing Tris-borate/EDTA buffer (TBE). The DNA was visualized under UV transillumination using ethidium bromide staining.
Detached and attached PC3 prostate cancer cells were incubated for 48 h with 0 and 100 pg/ml MCC. Detached cells treated with 100 pg/ml MCC showed significant DNA fragmentation (Fig. 5, lanes 3 and 4), whereas detached cells treated with 0 pg/ml MCC showed no fragmentation (Fig. 5, lane 1). Attached cells treated with 100pg/ml MCC showed no DNA fragmentation (Fig. 5, lane 2).
These data show that MCC induces apoptosis, as indicated by DNA
fragmentation, in detached androgen-independent prostate cancer cells in the absence of immune effector cells.
Induction of apoptosis as indicated by NuMA release The induction of apoptosis may also be demonstrated by the solubilization and release of nuclear matrix (NuMA) protein. LNCaP prostate cancer cells were incubated for 48 h with 0, 100, 200 and 300 pg/ml MCC while PC3 prostate cancer cells were incubated for 48 h with 0, 100 and 300 pg/ml MCC. Medium was drawn off, centrifuged at 10,000 X G
and the supernatant was frozen at -20 C until assayed for NuMA (Miller et al.
Biotech.
15:1042, 1993).
LNCaP prostate cancer cells treated with 100, 200, or 300 pg/ml MCC released 20%, 50% and 135%, respectively, more NuMA proteins into the medium than did cells treated with 0 pg/ml MCC (Fig. 6A). PC3 prostate cancer cells treated with 100 and 300 pg/ml MCC released 24% more NuMA proteins into the medium than did cells treated with 0 pg/ml MCC (Fig. 6B). These date demonstrate that MCC induces apoptosis, as indicated by NuMA release, in androgen-independent prostate cancer cells in the absence of immune effector cells.
Effect of MCC and M-DNA on IL-12 and TNF-a synthesis by monocytes and LNCaP
cells Human monocytic THP-1 cells were obtained from the ATCC and were cultured as recommended by the supplier. THP-1 cells (1 x 106 cells/ml) and LNCaP cells (3 x 105 cells/ml) were incubated with 0, 0.1 and 10 pg/ml MCC for 48 hours in 5% C02 in 6-well flat bottom microplates. At 48 hours, supernatants were collected and the presence of IL-12 and TNF-a was determined using commercial ELISA kits (Biosource, Camarillo, CA, USA). MCC and M-DNA induced synthesis of IL-12 (Table 3) and TNF-a Table 4 by immune system cells, THP-1 monocytes, and by LNCaP prostate tumor cells. The cytokines IL-12 and TNF-a both have been demonstrated to have anti-neoplastic activity against a range of cancer cells, including prostate cancer cells (Izquierdo et al.
Anticancer Drugs 7:
275, 1996; Sensibar et al. Cancer Res. 55: 2431, 1995).
Table 3 Induction of IL-12 by MCC and M-DNA
Cells No MCC (pg/ml) M-DNA (pg/ml) treatment 0.1 1.0 10.0 0.1 1.0 10.0 THP-1 3.3 148.9 1080.3 1032.0 132.5 949.8 925.7 LNCaP 0.1 1.1 31.3 103.6 0.9 5.4 40.0 Table 4 Induction of TNF-a by MCC and M-DNA
Cells No MCC (pg/ml) M-DNA (pg/ml) treatment 0.1 1.0 10.0 0.1 1.0 10.0 THP-1 3.3 245.4 390.0 329.7 230.0 360.3 315.6 LNCaP 0.1 186.3 338.7 284.6 n.d. n.d. n.d.
Effects of MCC, M-DNA and DNase I treated MCC on PC3 tumors in mice Androgen-independent PC3 prostate cancer cells are implanted subcutaneously into 40 male nude BALB/c mice and allowed to grow until palpable (0.1 to 0.5 cm in diameter). The mice are divided into 4 groups and tumor mass is measured in each mouse.
The 10 mice in Group 1 each receive saline. The 10 mice in Group 2 each receive saline containing MCC. The 10 mice in Group 3 each receive saline containing M-DNA.
The 10 mice in Group 4 each receive DNase I treated MCC. After 4 weeks of once per week intra-tumoral treatments, the mice are sacrificed and the tumor mass and number of metastases are determined. The mice in Group 2 and in Group 3 have less tumor mass and fewer metastases than the mice in Group 1 and in Group 4.
Effects of MCC and of M-DNA alone and in combination with estramustine and etoposide on PC3 tumors in mice Androgen-independent PC3 prostate cancer cells are implanted subcutaneously into 60 male nude BALB/c mice and allowed to grow until palpable (0.1 to 0.5 cm in diameter). The mice are divided into 6 groups and tumor mass is measured in each mouse.
The 10 mice in Group 1 receive saline. The 10 mice in Group 2 receive MCC in saline. The 10 mice in Group 3 receive M-DNA in saline. The 10 mice in Group 4 receive estramustine and etoposide in saline. The 10 mice in Group 5 receive MCC in combination with estramustine and etoposide in saline. The 10 mice in Group 6 receive M-DNA in combination with estramustine and etoposide in saline. After 4 weeks of once per week intra-tumoral treatment the mice are sacrificed and tumor mass and number of metastases are determined. The mice in Group 1 have the most tumor mass. The mice in Group 4 have less tumor mass than the mice in Group 1. The mice in Group 2 and Group 3 have less tumor mass than the mice in Group 4. The mice in Group 5 and in Group 6 have the least tumor mass.
Effects of MCC, M-DNA and DNase I treated MCC on LNCaP tumors in mice Androgen-dependent LNCaP prostate cancer cells are implanted subcutaneously into 40 male nude BALB/c mice and allowed to grow until palpable (0.1 to 0.5 cm in diameter). The mice are divided into 4 groups and tumor mass is measured in each mouse.
The 10 mice in Group 1 each receive saline. The 10 mice in Group 2 each receive saline containing MCC. The 10 mice in Group 3 each receive saline containing M-DNA.
The 10 mice in Group 4 each receive DNase I treated MCC. After 4 weeks of once per week intra-tumoral treatment the mice are sacrificed and the tumor mass and number of metastases are determined. The mice in Group 2 and in Group 3 have less tumor mass and fewer metastases than the mice in Group 1 and in Group 4.
Effects of MCC and of M-DNA alone and in combination with flutamide on LNCaP
tumors in mice Androgen-dependent LNCaP prostate cancer cells are implanted subcutaneously into 60 male nude BALB/c mice and allowed to grow until palpable (0.1 to 0.5 cm in diameter). The mice are divided into 6 groups and tumor mass is measured in each mouse.
The 10 mice in Group 1 receive saline. The 10 mice in Group 2 receive MCC in saline. The 10 mice in Group 3 receive M-DNA in saline. The 10 mice in Group 4 receive flutamide in saline. The 10 mice in Group 5 receive MCC in combination with flutamide in saline. The 10 mice in Group 6 receive M-DNA in combination with flutamide in saline.
After 4 weeks of once per week intra-tumoral treatment the mice are sacrificed and the tumor mass and number of metastases are determined. The mice in Group 1 have the most tumor mass. The mice in Group 4 have less tumor mass than the mice in Group 1. The mice in Group 2 and Group 3 have less tumor mass than the mice in Group 4. The mice in Group 5 and in Group 6 have the least tumor mass.
It should be understood, of course, that the foregoing relates only to a preferred embodiment of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the invention as set forth in the appended claims.
Ten p1 of 0.5 mg/ml RNase A (Sigma-Aldrich Canada) was added to each sample and the incubation was continued for 1 h. Samples were heated to 65 C and 10 p1 of 10 mM EDTA
(pH 8.0) containing 1 % (w/v) low-gelling-temperature agarose, 0.25 % (w/v) bromophenol blue, 40 % (w/v) sucrose was mixed with each sample. The samples were electrophoresed at 100 V for 3 h in a 2 % agarose gel containing Tris-borate/EDTA buffer (TBE). The DNA was visualized under UV transillumination using ethidium bromide staining.
Detached and attached PC3 prostate cancer cells were incubated for 48 h with 0 and 100 pg/ml MCC. Detached cells treated with 100 pg/ml MCC showed significant DNA fragmentation (Fig. 5, lanes 3 and 4), whereas detached cells treated with 0 pg/ml MCC showed no fragmentation (Fig. 5, lane 1). Attached cells treated with 100pg/ml MCC showed no DNA fragmentation (Fig. 5, lane 2).
These data show that MCC induces apoptosis, as indicated by DNA
fragmentation, in detached androgen-independent prostate cancer cells in the absence of immune effector cells.
Induction of apoptosis as indicated by NuMA release The induction of apoptosis may also be demonstrated by the solubilization and release of nuclear matrix (NuMA) protein. LNCaP prostate cancer cells were incubated for 48 h with 0, 100, 200 and 300 pg/ml MCC while PC3 prostate cancer cells were incubated for 48 h with 0, 100 and 300 pg/ml MCC. Medium was drawn off, centrifuged at 10,000 X G
and the supernatant was frozen at -20 C until assayed for NuMA (Miller et al.
Biotech.
15:1042, 1993).
LNCaP prostate cancer cells treated with 100, 200, or 300 pg/ml MCC released 20%, 50% and 135%, respectively, more NuMA proteins into the medium than did cells treated with 0 pg/ml MCC (Fig. 6A). PC3 prostate cancer cells treated with 100 and 300 pg/ml MCC released 24% more NuMA proteins into the medium than did cells treated with 0 pg/ml MCC (Fig. 6B). These date demonstrate that MCC induces apoptosis, as indicated by NuMA release, in androgen-independent prostate cancer cells in the absence of immune effector cells.
Effect of MCC and M-DNA on IL-12 and TNF-a synthesis by monocytes and LNCaP
cells Human monocytic THP-1 cells were obtained from the ATCC and were cultured as recommended by the supplier. THP-1 cells (1 x 106 cells/ml) and LNCaP cells (3 x 105 cells/ml) were incubated with 0, 0.1 and 10 pg/ml MCC for 48 hours in 5% C02 in 6-well flat bottom microplates. At 48 hours, supernatants were collected and the presence of IL-12 and TNF-a was determined using commercial ELISA kits (Biosource, Camarillo, CA, USA). MCC and M-DNA induced synthesis of IL-12 (Table 3) and TNF-a Table 4 by immune system cells, THP-1 monocytes, and by LNCaP prostate tumor cells. The cytokines IL-12 and TNF-a both have been demonstrated to have anti-neoplastic activity against a range of cancer cells, including prostate cancer cells (Izquierdo et al.
Anticancer Drugs 7:
275, 1996; Sensibar et al. Cancer Res. 55: 2431, 1995).
Table 3 Induction of IL-12 by MCC and M-DNA
Cells No MCC (pg/ml) M-DNA (pg/ml) treatment 0.1 1.0 10.0 0.1 1.0 10.0 THP-1 3.3 148.9 1080.3 1032.0 132.5 949.8 925.7 LNCaP 0.1 1.1 31.3 103.6 0.9 5.4 40.0 Table 4 Induction of TNF-a by MCC and M-DNA
Cells No MCC (pg/ml) M-DNA (pg/ml) treatment 0.1 1.0 10.0 0.1 1.0 10.0 THP-1 3.3 245.4 390.0 329.7 230.0 360.3 315.6 LNCaP 0.1 186.3 338.7 284.6 n.d. n.d. n.d.
Effects of MCC, M-DNA and DNase I treated MCC on PC3 tumors in mice Androgen-independent PC3 prostate cancer cells are implanted subcutaneously into 40 male nude BALB/c mice and allowed to grow until palpable (0.1 to 0.5 cm in diameter). The mice are divided into 4 groups and tumor mass is measured in each mouse.
The 10 mice in Group 1 each receive saline. The 10 mice in Group 2 each receive saline containing MCC. The 10 mice in Group 3 each receive saline containing M-DNA.
The 10 mice in Group 4 each receive DNase I treated MCC. After 4 weeks of once per week intra-tumoral treatments, the mice are sacrificed and the tumor mass and number of metastases are determined. The mice in Group 2 and in Group 3 have less tumor mass and fewer metastases than the mice in Group 1 and in Group 4.
Effects of MCC and of M-DNA alone and in combination with estramustine and etoposide on PC3 tumors in mice Androgen-independent PC3 prostate cancer cells are implanted subcutaneously into 60 male nude BALB/c mice and allowed to grow until palpable (0.1 to 0.5 cm in diameter). The mice are divided into 6 groups and tumor mass is measured in each mouse.
The 10 mice in Group 1 receive saline. The 10 mice in Group 2 receive MCC in saline. The 10 mice in Group 3 receive M-DNA in saline. The 10 mice in Group 4 receive estramustine and etoposide in saline. The 10 mice in Group 5 receive MCC in combination with estramustine and etoposide in saline. The 10 mice in Group 6 receive M-DNA in combination with estramustine and etoposide in saline. After 4 weeks of once per week intra-tumoral treatment the mice are sacrificed and tumor mass and number of metastases are determined. The mice in Group 1 have the most tumor mass. The mice in Group 4 have less tumor mass than the mice in Group 1. The mice in Group 2 and Group 3 have less tumor mass than the mice in Group 4. The mice in Group 5 and in Group 6 have the least tumor mass.
Effects of MCC, M-DNA and DNase I treated MCC on LNCaP tumors in mice Androgen-dependent LNCaP prostate cancer cells are implanted subcutaneously into 40 male nude BALB/c mice and allowed to grow until palpable (0.1 to 0.5 cm in diameter). The mice are divided into 4 groups and tumor mass is measured in each mouse.
The 10 mice in Group 1 each receive saline. The 10 mice in Group 2 each receive saline containing MCC. The 10 mice in Group 3 each receive saline containing M-DNA.
The 10 mice in Group 4 each receive DNase I treated MCC. After 4 weeks of once per week intra-tumoral treatment the mice are sacrificed and the tumor mass and number of metastases are determined. The mice in Group 2 and in Group 3 have less tumor mass and fewer metastases than the mice in Group 1 and in Group 4.
Effects of MCC and of M-DNA alone and in combination with flutamide on LNCaP
tumors in mice Androgen-dependent LNCaP prostate cancer cells are implanted subcutaneously into 60 male nude BALB/c mice and allowed to grow until palpable (0.1 to 0.5 cm in diameter). The mice are divided into 6 groups and tumor mass is measured in each mouse.
The 10 mice in Group 1 receive saline. The 10 mice in Group 2 receive MCC in saline. The 10 mice in Group 3 receive M-DNA in saline. The 10 mice in Group 4 receive flutamide in saline. The 10 mice in Group 5 receive MCC in combination with flutamide in saline. The 10 mice in Group 6 receive M-DNA in combination with flutamide in saline.
After 4 weeks of once per week intra-tumoral treatment the mice are sacrificed and the tumor mass and number of metastases are determined. The mice in Group 1 have the most tumor mass. The mice in Group 4 have less tumor mass than the mice in Group 1. The mice in Group 2 and Group 3 have less tumor mass than the mice in Group 4. The mice in Group 5 and in Group 6 have the least tumor mass.
It should be understood, of course, that the foregoing relates only to a preferred embodiment of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the invention as set forth in the appended claims.
Claims (23)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A use of a composition comprising:
(a) M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M.
phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA; and (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer.
(a) M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M.
phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA; and (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer.
2. The use of claim 1, wherein the pharmaceutically acceptable carrier is M.
phlei mycobacterial cell wall (MCC).
phlei mycobacterial cell wall (MCC).
3. The use of claim 2, wherein the M. phlei mycobacterial DNA (M-DNA) is preserved and complexed on the M. phlei mycobacterial cell wall (MCC).
4. The use of any one of claims 1 to 3, wherein the prostate cancer is hormone-sensitive prostate cancer.
5. The use of any one of claims 1 to 3, wherein the prostate cancer is hormone-insensitive prostate cancer.
6. The use of claim 4 or 5, wherein the hormone is an androgen.
7. The use of claim 6, wherein the androgen is testosterone.
8. A use of a composition comprising:
(a) M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M.
phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA; and (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer wherein the inhibition of proliferation of said prostate cancer cells is caused by induction of apoptosis in the prostate cancer cells, induction of cytokine synthesis in the prostate cancer cells, or induction of cytokine synthesis by immune cells in the prostate.
(a) M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M.
phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA; and (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer wherein the inhibition of proliferation of said prostate cancer cells is caused by induction of apoptosis in the prostate cancer cells, induction of cytokine synthesis in the prostate cancer cells, or induction of cytokine synthesis by immune cells in the prostate.
9. The use of claim 8, wherein the cytokine is IL-12 or TNF-.alpha..
10. The use of any one of claims 1 to 9, wherein the pharmaceutically acceptable carrier is a solid carrier, a liquid carrier, or combination of a solid and liquid carrier.
11. The use of any one of claims 1 to 10, further comprising using anti-androgenic agents, chemotherapeutic agents, steroids, or immunological agents.
12. A use of a composition comprising:
(a) M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M.
phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA, wherein the mycobacterial DNA is preserved and complexed on M. phlei mycobacterial cell wall (MCC); and, (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer.
(a) M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M.
phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA, wherein the mycobacterial DNA is preserved and complexed on M. phlei mycobacterial cell wall (MCC); and, (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer.
13. The use of claim 12, wherein the prostate cancer is hormone-sensitive prostate cancer.
14. The use of claim 12, wherein the prostate cancer is hormone-insensitive prostate cancer.
15. The use of claim 13 or 14, wherein the hormone is an androgen.
16. The use of claim 15, wherein the androgen is testosterone.
17. The use of any one of claims 12 to 16, wherein the inhibition of proliferation of said prostate cancer cells is caused by induction of apoptosis in the prostate cancer cells, induction of cytokine synthesis in the prostate cancer cells, or induction of cytokine synthesis by immune cells in the prostate.
18. A use of a composition comprising:
(a) M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M.
phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA, wherein the mycobacterial DNA is preserved and complexed on M. phlei mycobacterial cell wall (MCC); and, (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer, wherein the inhibition of proliferation of said prostate cancer cells is caused by induction of apoptosis in the prostate cancer cells, induction of cytokine synthesis in the prostate cancer cells, or induction of cytokine synthesis by immune cells in the prostate.
(a) M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M.
phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA, wherein the mycobacterial DNA is preserved and complexed on M. phlei mycobacterial cell wall (MCC); and, (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer, wherein the inhibition of proliferation of said prostate cancer cells is caused by induction of apoptosis in the prostate cancer cells, induction of cytokine synthesis in the prostate cancer cells, or induction of cytokine synthesis by immune cells in the prostate.
19. The use of any one of claims 12 to 18, wherein the pharmaceutically acceptable carrier is a solid carrier, a liquid carrier, or a combination of a solid and liquid carrier.
20. The use of any one of claims 12 to 19, further comprising using anti-androgenic agents, chemotherapeutic agents, steroids, or immunological agents.
21. A use of a composition comprising:
(a) a predetermined amount of M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M. phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA; and, (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer, wherein the amount of M-DNA used is from about 0.00001 to about 200 mg/kg per dose.
(a) a predetermined amount of M. phlei mycobacterial DNA (M-DNA) obtained from a disrupted M. phlei mycobacterium using DNase-free reagents in order to at least partially preserve the DNA; and, (b) a pharmaceutically acceptable carrier, for inhibiting proliferation of prostate cancer cells in an animal or human having prostate cancer, wherein the amount of M-DNA used is from about 0.00001 to about 200 mg/kg per dose.
22. The use of claim 21, wherein the amount of M-DNA is used in an amount from about 0.0001 to about 100 mg/kg per dose.
23. The use of claim 21, wherein the amount of M-DNA is used in an amount from about 0.001 to about 50 mg/kg per dose.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12745199P | 1999-04-01 | 1999-04-01 | |
| US60/127,451 | 1999-04-01 | ||
| PCT/CA2000/000342 WO2000059518A2 (en) | 1999-04-01 | 2000-03-30 | Composition and method for inducing apoptosis in prostate cancer cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2366090A1 CA2366090A1 (en) | 2000-10-12 |
| CA2366090C true CA2366090C (en) | 2011-05-24 |
Family
ID=22430191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2366090A Expired - Fee Related CA2366090C (en) | 1999-04-01 | 2000-03-30 | Composition and method for inducing apoptosis in prostate cancer cells |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1165106B8 (en) |
| JP (1) | JP2002541114A (en) |
| AT (1) | ATE296106T1 (en) |
| AU (1) | AU780909B2 (en) |
| CA (1) | CA2366090C (en) |
| CY (1) | CY1107455T1 (en) |
| DE (1) | DE60020352T2 (en) |
| ES (1) | ES2238996T3 (en) |
| PT (1) | PT1165106E (en) |
| WO (1) | WO2000059518A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4488626B2 (en) * | 1998-12-04 | 2010-06-23 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | Inflammation treatment |
| US20030044352A1 (en) * | 2001-04-24 | 2003-03-06 | Phillips Nigel C. | Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1003525E (en) * | 1997-08-05 | 2003-03-31 | Bioniche Life Sciences Inc | COMPOSITION AND METHOD FOR REGULATION OF PROLIFERATION AND CELL DEATH |
-
2000
- 2000-03-30 PT PT00912310T patent/PT1165106E/en unknown
- 2000-03-30 AT AT00912310T patent/ATE296106T1/en active
- 2000-03-30 DE DE60020352T patent/DE60020352T2/en not_active Expired - Lifetime
- 2000-03-30 WO PCT/CA2000/000342 patent/WO2000059518A2/en not_active Ceased
- 2000-03-30 EP EP00912310A patent/EP1165106B8/en not_active Expired - Lifetime
- 2000-03-30 AU AU34135/00A patent/AU780909B2/en not_active Ceased
- 2000-03-30 CA CA2366090A patent/CA2366090C/en not_active Expired - Fee Related
- 2000-03-30 ES ES00912310T patent/ES2238996T3/en not_active Expired - Lifetime
- 2000-03-30 JP JP2000609081A patent/JP2002541114A/en active Pending
-
2005
- 2005-08-03 CY CY20051100946T patent/CY1107455T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1165106A2 (en) | 2002-01-02 |
| DE60020352D1 (en) | 2005-06-30 |
| WO2000059518A3 (en) | 2001-02-01 |
| CY1107455T1 (en) | 2012-12-19 |
| AU780909B2 (en) | 2005-04-21 |
| EP1165106B1 (en) | 2005-05-25 |
| AU3413500A (en) | 2000-10-23 |
| PT1165106E (en) | 2005-10-31 |
| JP2002541114A (en) | 2002-12-03 |
| WO2000059518A2 (en) | 2000-10-12 |
| DE60020352T2 (en) | 2005-10-20 |
| EP1165106B8 (en) | 2005-07-27 |
| ES2238996T3 (en) | 2005-09-16 |
| ATE296106T1 (en) | 2005-06-15 |
| CA2366090A1 (en) | 2000-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008208140A (en) | Composition and method for regulating cell proliferation and cell death | |
| CN102149391A (en) | Compositions and methods for treatment of neoplastic disease | |
| CA2366090C (en) | Composition and method for inducing apoptosis in prostate cancer cells | |
| US6794368B1 (en) | Composition and method for inducing apoptosis in prostate cancer cells | |
| AU751667B2 (en) | Composition and method for the treatment of bladder cancer | |
| EP1135161B1 (en) | Chemotherapeutic composition and method | |
| CA2354047C (en) | Method for the treatment of inflammation | |
| HK1030887B (en) | Treatment of bladder cancer by mycobacterium phlei cell wall | |
| MXPA00001272A (en) | Composition and method for regulating cell proliferation and cell death |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160330 |